Frederic Stauffer

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Journal: Journal of medicinal chemistry

Published: May 02, 2022

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Journal: Blood

Published: April 01, 2020

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Journal: ACS medicinal chemistry letters

Published: October 01, 2019

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

Journal: Oncotarget

Published: June 17, 2019

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Journal: ACS medicinal chemistry letters

Published: December 23, 2016

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Journal: ACS medicinal chemistry letters

Published: April 21, 2016

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Journal: ACS medicinal chemistry letters

Published: April 21, 2016

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Journal: ACS medicinal chemistry letters

Published: March 17, 2016

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 21, 2016

Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.

Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 21, 2016

A General Strategy for Targeting Drugs to Bone.

A General Strategy for Targeting Drugs to Bone.

Journal: Angewandte Chemie (International ed. in English)

Published: July 30, 2015

Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding.

Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding.

Journal: ChemMedChem

Published: July 30, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026